IRESSA 250 (Iressa 250 mg)

Generic Name: gefitinib

Pill imprint IRESSA 250 has been identified as Iressa 250 mg.

Iressa is used in the treatment of non-small cell lung cancer and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iressa 250 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for IRESSA 250

Iressa 250 mg IRESSA 250
Iressa
Generic Name:
gefitinib
Imprint:
IRESSA 250
Strength:
250 mg
Color:
Brown
Size:
11.00 mm
Shape:
Round
Availability:
Prescription only
Drug Class:
EGFR inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
AstraZeneca Pharmaceuticals
National Drug Code (NDC):
00310-0482
Inactive Ingredients:
lactose monohydrate
microcrystalline cellulose
croscarmellose sodium
povidone
sodium lauryl sulfate
magnesium stearate
hypromelloses
polyethylene glycol 300
titanium dioxide
ferric oxide red
ferric oxide yellow

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web5)